A juvenile case of epilepsy‐associated, isocitrate dehydrogenase wild‐type/histone 3 wild‐type diffuse glioma with a rare BRAFA598T mutation. Issue 6 (29th September 2020)

• Record Type: Journal Article
• Authors: Sadashima, Shoko; Suzuki, Satoshi O.; Haruyama, Hironori; Mukae, Nobutaka; Fujioka, Yutaka; Hata, Nobuhiro; Mizoguchi, Masahiro; Ishimatsu, Keisuke; Hiwatashi, Akio; Iwaki, Toru
• Is Part Of: Neuropathology. Volume 40:Issue 6(2020)
• Page Start: 646
• Page End: 650
• Publication Date: 2020-09-29
• Subjects: BRAF -- CD34 -- diffuse glioma -- epilepsy -- MAPK pathway; Nervous system -- Diseases -- Periodicals; Nervous system -- Pathophysiology -- Periodicals; 616.8047
• DOI: 10.1111/neup.12693
• Languages: English
• ISSNs: 0919-6544

Abstract

Abstract : Here, we report a juvenile (18‐year‐old male) case of epilepsy‐associated, isocitrate dehydrogenase wild‐type/histone 3 wild‐type diffuse glioma with a rare BRAF mutation and a focal atypical feature resembling diffuse astrocytoma. The patient presented with refractory temporal lobe epilepsy. Subsequently, magnetic resonance imaging revealed a hyperintense lesion in the right temporal lobe on fluid attenuated inversion recovery images. The patient underwent right lateral temporal lobectomy and amygdalohippocampectomy. Histopathologically, the tumor showed isomorphic, diffuse, infiltrative proliferation of glial tumor cells and intense CD34 immunoreactivity. The tumor cells were immunonegative for isocitrate dehydrogenase 1 (IDH1) R132H and BRAF V600E. Notably, the tumor cells showed the lack of nuclear staining for α‐thalassemia/mental retardation syndrome, X‐linked (ATRX). In addition, the Ki‐67 labeling index, using a monoclonal antibody MIB‐1, was elevated focally at tumor cells with p53 immunoreactivity. Molecular analyses identified a BRAF A598T mutation, the first case reported in a glioma. BRAF A598T is predicted to result in loss of kinase action; however, inactive mutants can stimulate mitogen‐activated protein kinase kinase (MEK)‐extracellular signal‐regulated kinase (ERK) signaling through CRAF activation. Thus, according to the recent update of the consortium to inform molecular and practical approaches to central nervous system tumor taxonomy (cIMPACT‐NOW update 4), our case is also compatible with diffuse glioma with the mitogen‐activated protein kinase (MAPK) pathway alteration. Thorough immunohistochemical and molecular studies are necessary for diagnosis of epilepsy‐associated, diffuse gliomas. Partial resemblance in histopathological and molecular genetic features to diffuse astrocytoma also calls for attention.